Autologous hematopoietic cell transplantation (AHCT) has been a standard treatment for multiple myeloma (MM) for 40 years but is underused in racial and ethnic minority groups, despite the introduction of new therapies.*
-
An institutional review of 1266 MM patients from 2012 to 2022 found overall AHCT utilization at 76%, but only 64.7% in non-Hispanic Black (NHB) patients compared to higher rates in other groups, highlighting significant racial disparities.*
-
Key factors influencing AHCT utilization included patient age, health conditions, and caregiver support; while NHB utilization increased slightly over time, it still lagged behind non-Hispanic White
Vaccine-induced immune thrombotic thrombocytopenia (VITT) is a rare and life-threatening complication that can occur after COVID-19 vaccination. After the first reports of VITT and CVST in 2021 after Ad26.COV2.